We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Bio-Rad Laboratories, Inc. is among the ...
Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...
On February 17, 2026, Knoll Capital Management disclosed a purchase of 473,591 shares of Nuvation Bio (NYSE:NUVB), an estimated $2.93 million trade based on quarterly average pricing. Nuvation Bio is ...
The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...
For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...
Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Which news ...
Wedbush analyst David Nierengarten on Wednesday downgraded Generation Bio (GBIO) to ‘Neutral’ from ‘Outperform’ with a $7 price target after the company announced a strategic restructuring. Shares of ...
Zacks Investment Research on MSN
Kyntra Bio (KYNB) upgraded to buy: Here's what you should know
Kyntra Bio (KYNB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...
BIO-key International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric ...
Knoll Capital Management added 473,591 shares of Nuvation Bio in the fourth quarter; the estimated trade size was $2.93 million. Meanwhile, the quarter-end position value increased by $7.88 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results